
|Articles|August 1, 2002
Combination therapy lowers BPH progression risk by 67%
Orlando, FL-In a finding that will likely change the way physicianstreat patients with benign prostatic hyperplasia, the combination of twocommonly used drugs was shown to slow progression of the disease significantlybetter than placebo or either drug alone. In fact, treatment with the combinationof finasteride (Proscar) and doxazosin (Cardura) lowers the risk of BPHprogression by as much as 67% and the risk of urinary retention by as muchas 79%.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








